Subcutaneous or Intramuscular?
The route on a label is not a suggestion about comfort. It is the route the pharmacokinetics were measured in, and changing it changes what the dose data means.
The question is usually asked as though it were about preference — which one hurts less, which is easier to do alone, which people generally use.
It is not that kind of question. The route is part of the specification, in the same way the amount is. Changing it does not adjust a detail around the edge of a protocol; it changes what the protocol’s numbers refer to.
Two tissue compartments, not two techniques
A subcutaneous injection deposits into the layer of fat between the skin and the underlying muscle. A intramuscular injection deposits into the muscle itself.
The relevant difference is blood supply. Muscle is densely vascularised; the subcutaneous fat layer is not. Everything else follows from that.
| Subcutaneous | Intramuscular | |
|---|---|---|
| Tissue | Fat layer below the dermis | Muscle body |
| Blood supply | Comparatively sparse | Rich |
| Absorption | Slower, flatter | Faster, higher early peak |
| Typical needle | Short, fine | Longer, wider bore |
| Site selection | Reliable fat layer, few vessels | Muscle bulk, depth anatomy |
The absorption row is the one that matters. Everything above it is mechanism and everything below it is logistics.
Why the label specifies a route
A clinical trial does not establish that a substance works. It establishes that a particular amount, given a particular way, on a particular schedule, produced a particular result in a particular population.
The route is one of those variables, not context around them.
The approved GLP-1 receptor agonists are labelled for subcutaneous use, and their pharmacokinetic characterisation — the absorption profile, the time to peak concentration, the exposure over a dosing interval — describes subcutaneous administration. That is the route in which the dose-response relationship was established.
Administer the same quantity intramuscularly and the quantity is unchanged while the exposure curve is not. Peak concentration and the shape of the curve between doses both shift. The trial data has not become wrong; it has become a description of something you did not do.
This is the general form of a mistake that recurs across peptide practice: treating a studied protocol as a collection of independent settings that can be adjusted one at a time. Dose, route, schedule and formulation were studied as a package. Pull one out and the evidence does not follow it.
The accidental route change
The distinction is not always deliberate. A subcutaneous injection becomes an intramuscular one when the needle is longer than the subcutaneous tissue is thick at that site.
Subcutaneous thickness is not a constant. It varies between people and between sites on the same person — abdomen, thigh and upper arm are genuinely different, and body composition changes the picture again. This is precisely why needle length and site are specified rather than left to judgement, and why copying another person’s setup is unreliable.
The practical consequence is that “I injected subcutaneously” is a statement about intent. Whether it was true depends on needle length, site, technique and the tissue that was actually there.
An unexpectedly rapid or unexpectedly strong effect sometimes has a purely mechanical explanation, and it is worth ruling that out before reaching for a pharmacological one.
Sites are not a shared list
Because the two routes are avoiding different problems, they select sites on different criteria.
Subcutaneous sites are chosen for having a dependable fat layer with few large vessels or nerves immediately beneath. Intramuscular sites are chosen for muscle bulk and for the anatomy that must be avoided at depth — which is a more consequential question, because the structures at risk are deeper and larger.
A site that is standard for one route can be inappropriate for the other. The lists overlap in name and not in reasoning.
Rotation also differs between them. Rotating subcutaneous sites is largely about avoiding local tissue change from repeated deposition in one place. The reasons to rotate intramuscular sites are not identical, and a rotation pattern designed for one route is not automatically sensible for the other.
Sterile technique is the part that does not vary
Whatever the route, the injection is a breach of the skin barrier, and the established principles for that are the same: hand hygiene, skin preparation, a sterile single-use needle, no re-entry with a used needle, and safe sharps disposal.
The WHO toolkit on injection practice covers this ground for intradermal, subcutaneous and intramuscular routes together, because the infection-control requirements do not change with depth even though the anatomy does.
This is also where the diluent choice connects: a multi-dose vial entered repeatedly is a contamination question that sits alongside the route question rather than inside it.
What this means in practice
If a product has a label, the route on it is not a default that can be improved on. It is the route the evidence describes.
If a compound has no label — which is the situation for most of what gets discussed in this space — then there is no established route, because there is no established anything. The reasoning that produces a route recommendation for an unapproved compound is analogy, and it is worth being clear-eyed that this is what it is.
What is worth recording, either way, is the route and the site alongside the amount and the date. Those two fields are the first to blur after a few weeks, and they are the ones that turn “this felt different” from a vague impression into something with a possible explanation.
Frequently asked questions
What is the actual difference between subcutaneous and intramuscular?
They are different tissue compartments with different blood supply. A subcutaneous injection goes into the fatty layer between the skin and the muscle. An intramuscular injection goes into the muscle itself, which is far more richly vascularised. That difference in blood supply is the whole point: muscle generally absorbs a substance faster and produces a higher, earlier peak concentration, while subcutaneous tissue absorbs more slowly and more evenly. The two routes also differ in needle length, technique and which sites are appropriate, but the absorption profile is what makes them non-interchangeable.
Why does the route on the label matter so much?
Because the dose and the route were studied together. When a trial establishes that a given amount produces a given effect with a given safety profile, that finding belongs to the route it was administered by. The approved GLP-1 receptor agonists — semaglutide and tirzepatide among them — are labelled for subcutaneous use, and their pharmacokinetic data describes subcutaneous administration. Give the same amount intramuscularly and the absorption curve changes shape. The number on the syringe has not changed, but what that number means has, and the trial data no longer describes what you did.
Can a subcutaneous injection end up intramuscular by accident?
Yes, and it is one of the more common technique errors. If the needle is longer than the subcutaneous tissue is thick at that site, it reaches muscle. Subcutaneous thickness varies enormously between individuals and between sites on the same individual — the abdomen, thigh and upper arm are not equivalent. This is why needle length, site choice and technique are specified rather than left open, and why a site that works for one person is not automatically right for another. It is also a reason an unexpectedly fast or strong effect sometimes has a mechanical explanation.
Does the route affect where I can inject?
Yes, substantially. The sites appropriate for subcutaneous administration are chosen for having a reliable fat layer and few large vessels or nerves beneath it. Intramuscular sites are chosen on entirely different criteria — muscle bulk and the anatomy that has to be avoided at depth. They are not the same list, and a site that is standard for one route can be inappropriate for the other. Rotation also works differently between them, because the tissue problem being avoided is not the same one.